证监会严肃查处长药控股严重财务造假案件。 据证监会网站12月26日消息，近日，证监会对上市公司长江医药控股股份有限公司（简称"*ST长药 "，股票代码：300391 ）涉嫌定期报告 等财务数据存在虚假记载作出行政处罚事先告知。 经查，*ST长药连续三年虚增收入和利润，违反证券法律法规。证监会拟对上市公司罚款1000万元，对14名责任人合计罚款3100万元，对 公司原总经理罗明采取终身证券市场禁入措施。 *ST长药涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。证监会对中介机构执业情况同步开展核查，一旦发现违法违规情 形，将依法予以惩处。对于可能涉及的犯罪线索，证监会将坚持应移尽移的工作原则，严格按照《刑法》《最高人民检察院 公安部关于公 安机关管辖的刑事案件立案追诉标准的规定（二）》的规定移送公安机关。 同日，*ST长药发布多则公告。公告显示，公司及相关人员于2025年12月26日收到中国证监会下发的《行政处罚事先告知书》（以下简 称"《告知书》"）。 根据《告知书》认定的事实，公司2021年、2022年、2023年年度报告存在虚假记载，2021年至2023年年度报告分别虚增营业收入 21532.38 ...

证监会对中介机构执业情况同步开展核查，一旦发现违法违规情形，将依法予以惩处。 对于可能涉及的犯罪线索，证监会将坚持应移尽移的工作原则，严格按照《刑法》《最高人民检察院 公安部关于公安机关管辖的刑事案件立案追诉标准的规定（二）》的规定移送公安机关。 来源｜证监会网站 近日，证监会对上市公司长江医药控股股份有限公司（简称 * ST长药）涉嫌定期报告等财务数据存在 虚假记载作出行政处罚事先告知。 经查， * ST长药连续三年虚增收入和利润，违反证券法律法规。证监会拟对上市公司罚款1000万 元，对14名责任人合计罚款3100万元，对公司原总经理罗明采取终身证券市场禁入措施。 * ST长药涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。 编辑 ｜瑜见 ...

（免责声明：文章内容和数据仅供参考，不构成投资建议。投资者据此操作，风险自担。） 编辑|何小桃 易启江 每经编辑｜何小桃 据证监会网站12月26日消息，近日，证监会对上市公司长江医药控股股份有限公司（简称*ST长药，300391）涉嫌定期报告等财务数据存在虚假记载作出 行政处罚事先告知。 经查，*ST长药连续三年虚增收入和利润，违反证券法律法规。证监会拟对上市公司罚款1000万元，对14名责任人合计罚款3100万元，对公司原总经理罗 明采取终身证券市场禁入措施。*ST长药涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。 证监会对中介机构执业情况同步开展核查，一旦发现违法违规情形，将依法予以惩处。对于可能涉及的犯罪线索，证监会将坚持应移尽移的工作原则，严 格按照《刑法》《最高人民检察院 公安部关于公安机关管辖的刑事案件立案追诉标准的规定（二）》的规定移送公安机关。 12月26日，*ST长药收跌3.92%，每股报1.47元，总市值5.1亿元。 校对|段炼 每日经济新闻综合证监会网站 ...

近日，证监会对上市公司长江医药控股股份有限公司（简称*ST长药）涉嫌定期 报告等财务数据存在虚假记载作出行政处罚事先告知。经查，*ST长药连续三年虚增 收入和利润，违反证券法律法规。证监会拟对上市公司罚款1000万元，对14名责任人 合计罚款3100万元，对公司原总经理罗明采取终身证券市场禁入措施。*ST长药涉嫌 触及重大违法强制退市情形，深交所将依法启动退市程序。证监会对中介机构执业情 况同步开展核查，一旦发现违法违规情形，将依法予以惩处。对于可能涉及的犯罪线 索，证监会将坚持应移尽移的工作原则，严格按照《刑法》《最高人民检察院 公安部 关于公安机关管辖的刑事案件立案追诉标准的规定（二）》的规定移送公安机关。 ...

关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、涉嫌财报虚假记载 12月22日晚，长药控股发布《关于立案调查进展暨风险提示公告》称，公司存在重大违法强制退市风 险、不符合重整条件的风险及财务类强制退市风险。 11月7日，*ST长药（维权）披露公告称因涉财报虚假记载，根据相关法律法规证监会对其立案调查。 这一立案调查意味着*ST长药可能涉嫌财务造假，正式调查结束后，如果违法行为被确认，公司将面临 严重后果。 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 上海沪紫律师事务所刘鹏律师提示投资者索赔唯有主动通过法律途径维权，才能弥补部分损失。（刘鹏 律师专栏） （2）于2025年11月7日（含当日）之前买入，并在2025年11月8日之后卖出或仍持有而亏。 二、两类投资者可维权 *ST长药目前面临多重退市风险，而证监会的立案调查只是其中之一。目前债务缠身、财务状况恶化以 及公司治理和内部控制方面存在严重缺陷。 值得注意的是此前长药控股因资金占用引发的投资者索赔案件此前已获终审胜诉，且诉讼时效还未 ...

清越科技公告称，公司因涉嫌定期报告等财务数据虚假记载，于此前被中国证监会立案。若后续经行政 处罚认定的事实触及重大违法强制退市情形，公司股票将被强制退市。截至公告披露日，调查尚在进行 中，公司未收到结论性意见或决定。目前公司经营、业务及财务状况正常，将配合调查，每月披露一次 风险性提示公告。 ...

Core Viewpoint - The company Lifan Shuke Co., Ltd. is facing administrative penalties and potential delisting due to financial fraud involving inflated revenue and costs totaling 638 million yuan from 2021 to 2023 [1][2][3]. Group 1: Financial Misconduct - Lifan Shuke inflated its revenue and costs through agency business, financing trade, and fictitious trade, resulting in a total inflated revenue of 638 million yuan and costs of 628 million yuan [1][4]. - The breakdown of inflated figures includes 280 million yuan in revenue and 277 million yuan in costs for 2021, 312 million yuan in revenue and 305 million yuan in costs for 2022, and 46 million yuan in revenue and 45 million yuan in costs for 2023 [1][4]. - The company engaged in financing trade that did not meet revenue recognition criteria, leading to further inflated financial statements [3][4]. Group 2: Regulatory Actions - The Anhui Securities Regulatory Bureau plans to impose a fine of 10 million yuan on Lifan Shuke and a total of 30 million yuan on 10 responsible individuals, including the chairman Wang Yi [1][4]. - The company is set to be delisted due to serious violations of securities laws, with trading of its stock suspended from December 1 and risk warnings implemented upon resumption [5][6]. - The case reflects a comprehensive regulatory approach that includes administrative penalties, market bans, criminal referrals, and accountability for intermediary institutions [2][7]. Group 3: Company Background and Performance - Lifan Shuke is a digital technology cloud service provider listed on the Shenzhen Stock Exchange since August 2012, focusing on new digital infrastructure [6]. - The company has reported continuous losses, with net losses of 623 million yuan in 2020, 9 million yuan in 2021, 155 million yuan in 2022, 124 million yuan in 2023, and 125 million yuan projected for 2024, totaling over 1 billion yuan in losses [6]. - Lifan Shuke is the 14th company this year facing potential delisting due to financial fraud, marking a record high for such cases [6].

12月1日，江苏吴中医药发展股份有限公司（*ST苏吴（600200）；600200.SH）发布公告称，公司已于12月1日收到上海证券交易所《关于江苏吴中医药发 展股份有限公司股票终止上市的决定》。根据该决定，公司股票自12月9日起进入为期15个交易日的退市整理期，预计最后交易日为12月29日。退市整理期 届满后5个交易日内，上交所将对公司股票予以摘牌，公司股票终止上市。 来源：*ST苏吴公告 此次退市决定源于中国证监会于11月25日下发的《行政处罚决定书》（〔2025〕145号）。该处罚书认定，*ST苏吴在2020年至2023年连续四年年度报告中 存在虚假记载，包括虚增营业收入合计17.71亿元、虚增利润总额7599.75万元，并未披露关联方非经营性资金占用，截至2023年末占用余额高达16.93亿元， 占净资产比例达96.09%。上述行为构成《上海证券交易所股票上市规则（2025年4月修订）》第9.5.2条第一款第（六）项规定的重大违法强制退市情形。 早在2025年2月26日，*ST苏吴即因涉嫌信息披露违法违规被中国证监会立案调查。同年5月，公司董事长钱群山被单独立案。7月13日，公司收到《行政处 罚事先告 ...

Core Viewpoint - ST Lifan has been found to have inflated revenue for three consecutive years, with the inflated amounts exceeding 50% of total revenue in two of those years, leading to significant penalties and the risk of delisting [1][2]. Financial Misconduct - The company was discovered to have engaged in financial fraud, inflating revenue by a total of 638 million yuan from 2021 to 2023, with specific years showing inflated revenues of 280 million yuan, 312 million yuan, and 46 million yuan respectively [2][4]. - The inflated revenues accounted for 50.09% and 51.67% of total revenues in 2021 and 2022 respectively [2]. - The Anhui Securities Regulatory Bureau imposed a total fine of 40 million yuan on the company and ten responsible individuals, with penalties ranging from 1 million to 5 million yuan for individuals [2][4]. Administrative Proceedings - The case has entered the administrative penalty phase, allowing responsible parties to present their statements and request hearings, with the regulatory body set to review the findings [3]. Stock Status and Risks - Following the financial misconduct, ST Lifan's stock will be suspended from trading on December 1, with a name change to *ST Lifan, indicating a higher risk of delisting due to major violations [1][4]. - The company has received a "non-standard" opinion on its annual report, indicating issues with internal controls and accounting practices [4]. Financial Performance - ST Lifan has reported cumulative losses exceeding 1 billion yuan over the past five years, with net profits declining consistently [6]. - The company has been focusing on transforming its business model but continues to face challenges, including liquidity issues and asset impairments [6][7]. Bankruptcy Proceedings - The controlling shareholder is currently undergoing bankruptcy restructuring, with the application accepted by the court, indicating potential challenges in the company's financial stability [7]. - A significant portion of shares held by major shareholders is under judicial auction due to debt disputes, further complicating the company's financial situation [7].

Core Viewpoint - ST Lifan has been exposed for three consecutive years of financial fraud, leading to significant penalties and potential delisting from the stock market [1][3][6]. Group 1: Financial Fraud Details - From 2021 to 2023, ST Lifan inflated its revenue by a total of 638 million yuan and costs by 628 million yuan through various fraudulent activities [2]. - In 2021, the company inflated revenue by 280 million yuan and costs by 277 million yuan; in 2022, revenue was inflated by 312 million yuan and costs by 305 million yuan; in 2023, revenue was inflated by 46 million yuan and costs by 45 million yuan [7]. - The inflated revenue for 2021 and 2022 combined reached 592 million yuan, accounting for 50.91% of the total reported revenue for those years, triggering the threshold for mandatory delisting [7]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) plans to impose a fine of 10 million yuan on ST Lifan and a total of 30 million yuan on 10 responsible individuals, with three key individuals facing a 10-year ban from the securities market [3][12]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the serious violations, with ST Lifan's stock being suspended for one day and then relisted with a risk warning [3][12]. - The company has acknowledged that it may face delisting if the formal penalty decision confirms the serious violations [13]. Group 3: Audit and Accountability - The auditing firm Zhongxing Caiguanghua issued standard unqualified audit reports for ST Lifan's annual reports from 2021 to 2023, despite the fraudulent activities [14]. - The CSRC has decided to investigate the auditing firm's conduct, indicating potential penalties for failing to perform due diligence [15].